🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Recruitingn/aAges 18 Years - 85 YearsAllShanghai Pulmonary Hospital, Shanghai, China
NCT06900062 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Bronchiectasis is a heterogeneous airway disease with diverse causes, making precise diagnosis, prognosis, and treatment response prediction challenging. Identifying patient subgroups (phenotypes) and molecular profiles (endotypes) can enhance individualized assessment and management. While prior studies, primarily in European populations, have identified key phenotypes and endotypes, their relevance to Chinese patients remains unclear due to geographic and clinical differences. Specific causes of bronchiectasis, such as allergic bronchopulmonary aspergillosis (ABPA) and primary ciliary dyskinesia (PCD), may also exhibit distinct pathophysiology requiring further exploration. The C-BRIDGE Study seeks to characterize phenotypes and endotypes in Chinese bronchiectasis patients during stable disease and exacerbations, evaluate differences in clinical outcomes across these subgroups, and dev

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * A prior CT scan confirming bronchiectasis, accompanied by a compatible clinical syndrome including cough, sputum production, and/or recurrent respiratory tract infections. * At the screening visit, participants must have been clinically stable for 4 weeks, defined as no antibiotic or corticosteroid treatment for a pulmonary exacerbation in the preceding 4 weeks. Exclusion Criteria: * Inability to provide informed consent * Age under 18 years * Patients with active tuberculosis * Use of antibiotics or corticosteroids for a pulmonary exacerbation within the past 4 weeks
💊

What it tests

  • Not listed
📍

Where

9 sites
Lin Liu
Guiyang, China
Lei Song
Changchun, China
Qian Qi
Jinan, China
He-feng Chen
Shanghai, China
Zhou-fang Mei
Shanghai, China
Jun She
Shanghai, China
Xue-ling Wu
Shanghai, China
Yong-hua Gao
Shanghai, China

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy